Press Enter to search · ESC to close

Regulation

China’s Four Agencies Clarify Innovative Drugs Excluded from Outpatient Average Drug Cost Growth

China’s National Health Commission, National Healthcare Security Administration, National Administration of Traditional Chinese Medicine and National Disease Control and Prevention Administration issued a joint notice on the safe and rational use of innovative drugs. The notice sets out measures on promoting rational allocation, strengthening training guidance, optimizing use conditions and improving management practices, and clarifies that certain innovative drugs are not counted toward the growth rate of average outpatient drug costs.

Share

Related News

Cointime share card
Long-press the image to save or share
Pitch us Community Feedback